Gene therapy for lung neoplasms

Clinics in Chest Medicine

Volumn 23, Issue 1, 2002, Pages 265-277

  Albelda, Steven M ^a   Wiewrodt, Rainer ^a   Sterman, Daniel H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CISPLATIN; CYTOKINE; CYTOSINE DEAMINASE; ENDOSTATIN; FLUCYTOSINE; FRAGILE HISTIDINE TRIAD PROTEIN; GANCICLOVIR; I KAPPA B ALPHA; INTERFERON; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; ONYX 015; PACLITAXEL; PROTEIN BAX; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; RIBOZYME; SUPEROXIDE DISMUTASE; THYMIDINE KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN BINDING PROTEIN;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANTIGEN PRESENTING CELL; BACTERIUM; BYSTANDER EFFECT; CANCER CELL; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONJUGATE; DENDRITIC CELL; DRUG MECHANISM; DRUG RESPONSE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE THERAPY; HERPES VIRUS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENETICS; IN VIVO STUDY; INFLAMMATION; LENTIVIRINAE; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; MESOTHELIOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; RETROVIRUS; REVIEW; SIDE EFFECT; SUICIDE GENE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0036198732     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00072-8     Document Type: Review

References (71)

1. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells
2. Improving adenoviral vectors for cancer gene therapy
3. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
4. Development of lentiviral vectors for gene therapy for human diseases
5. Inhibition of tumorigenecity in lung adenocarcinoma cells by c-erbB-2 antisense expression
6. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin
7. Combination gene therapy for liver metastasis of colon carcinoma in vivo
8. Structure and function of lipid-DNA complexes for gene delivery
9. Strategies for enhancing viral-based gene therapy using ionizing radiation
10. Gene therapy approaches for inherited and acquired diseases of the lung
11. Lipoplexes and tumours. A review
12. Gene therapy for lung cancer
13. Transfection of anti-sense complementary DNA of human epidermal-growth-factor receptor attenuates the proliferation of human nonsmall-cell-lung-cancer cells
14. Cell death and cancer: Replacement of apoptopic genes and inactivation of death suppressor genes in therapy
15. Immune system in suicide-gene therapy
16. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
17. Phase 1 trial of recombinant adenovirus gene transfer in lung cancer
18. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins
19. erbB-2 knockout employing an intracellular single-chain antibody (sFV) accomplishes specific toxicity in erbB-2-expressing lung cancer cells
20. Replication-selective adenoviruses as oncolytic agents
21. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
22. Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vitro models of human malignant mesothelioma and lung cancer
23. Adenovirus-mediated p161INK4a gene expression radiosentizes non-small cell lung cancer cells in a p53-dependent manner
24. p185 neu expression in human lung adenocarcinomas predict shortened survival
25. Robbins PD-Retroviral vectors
26. Replication-selective microbiological agents: Fighting cancer with targeted germ warfare
27. Replication-selective virotherapy for cancer: Biological principals, risk management, and future directions
28. The treatment of malignant pleural mesothelioma with gene modified cancer cells: A Phase I study
29. Gene therapy strategies for tumor angiogenesis
30. Phase 1 trial of adenovirus p53 in bronchioalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage
31. Use of a "replication restricted" Herpes virus to treat localized human malignancy
32. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines
33. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication
34. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
35. Impact of pre-existing and induced humoral and cellular immune responses in an adenoviral-based gene therapy phase 1 clinical trial for localized malignancy
36. AAV vectors: Is clinical success on the horizon
37. Drug sensitivity ("suicide") genes for selective cancer therapy
38. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA
39. A phase I/II study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer
40. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
41. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
42. The role of the bystander effect in suicide gene therapy
43. Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors
44. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposomal vector
45. The evaluation of adenoviral p53-mediated bystander effect in gene therapy for cancer
46. Cytokine gene therapy or infusion as treatment for solid human cancer
47. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
48. Molecular and genetic aspects of lung cancer
49. Gene replacement strategies for lung cancer
50. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
51. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer: Results of a multicenter phase II study
52. A phase I study of adenovirus-mediated p53 gene transfer in patients with advanced non-small cell lung cancer
53. Gene therapy for malignant mesothelioma: A novel approach for an incurable cancer with increased incience in Louisiana
54. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
55. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma
56. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma
57. Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: Results of a phase 1 clinical trial in malignant mesothelioma
58. Adenovirus-mediated p53 gene transfer in advanced nonsmall cell lung cancer
59. IL-2 gene therapy of advanced lung cancer patients
60. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer
61. Phase 1 study of a recombinant adenovirus-mediated gene transfer in lung cancer pateints
62. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection
63. Synergy between the herpes simplex virus tklganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan
64. Methods of gene delivery
65. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
66. Advances in adenoviral vectors: From genetic engineering to their biology
67. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines
68. Development and application of adenoviral vectors for gene therapy of cancer
69. Antitumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice
70. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl- 2 coding sequence